Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
Clovis seeks U.S. approval for rucaparib as maintenance therapy for
women with recurrent ovarian cancer who are platinum sensitive, and in
complete or partial response to platinum chemotherapy, with no
requirement for diagnostic testing
Priority review granted based on positive data from phase 3 ARIEL3
clinical trial in which rucaparib significantly improved PFS in all
ovarian cancer patient populations studied
BOULDER, Colo.--(BUSINESS WIRE)--Nov. 8, 2017--
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief
Executive Officer and President, Patrick J. Mahaffy, will present at the
Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at
9:30 AM Eastern Time. The conference will be held at the Lotte New York
Palace Hotel in New York City.
A live webcast of the presentation can be accessed through the investor
Strong third quarter of launch for Rubraca®
(rucaparib) in U.S. with $16.8M reported in net sales
An additional $4.4M in commercial value was provided as free
drug through our patient assistance program
Submission of a supplemental New Drug Application (sNDA) for
rucaparib as maintenance treatment for patients with
platinum-sensitive recurrent ovarian cancer complet...
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.